: Clinical trial enrollment in oncology remains limited by increasingly complex eligibility criteria, biomarker stratification, and fragmented clinical data, contributing to prolonged recruitment timelines and low participation rates. This review examines contemporary pre-screening and screening approaches, spanning manual workflows, health-system-embedded digital tools, and emerging artificial intelligence-enabled methods. We assess the relative strengths and limitations of large language model-based strategies, including retrieval-augmented and domain-adapted approaches, in addressing scalability, accuracy, and equity challenges. Hybrid frameworks that integrate automated screening with clinician oversight appear most effective in improving trial matching efficiency, representativeness, and timely access to investigational therapies across diverse oncology populations.
A unified framework for pre-screening and screening tools in oncology clinical trials / Horgan, Denis; Paulson, Joe; Loaiza-Bonilla, Arturo; Svedman, Christer; Malapelle, Umberto; Lorca, Frédérique Penault; Rahsheed, Hadi Mohamad Abu; Hofman, Paul; Kachnowsk, Stan; Schneider, Daniel; Subbiah, Vivek. - In: NPJ PRECISION ONCOLOGY. - ISSN 2397-768X. - (2026). [10.1038/s41698-026-01306-3]
A unified framework for pre-screening and screening tools in oncology clinical trials
Malapelle, Umberto;
2026
Abstract
: Clinical trial enrollment in oncology remains limited by increasingly complex eligibility criteria, biomarker stratification, and fragmented clinical data, contributing to prolonged recruitment timelines and low participation rates. This review examines contemporary pre-screening and screening approaches, spanning manual workflows, health-system-embedded digital tools, and emerging artificial intelligence-enabled methods. We assess the relative strengths and limitations of large language model-based strategies, including retrieval-augmented and domain-adapted approaches, in addressing scalability, accuracy, and equity challenges. Hybrid frameworks that integrate automated screening with clinician oversight appear most effective in improving trial matching efficiency, representativeness, and timely access to investigational therapies across diverse oncology populations.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


